# Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

> **NCT02602314** · PHASE4 · UNKNOWN · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 450 (actual)

## Conditions studied

- Chronyc Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT02602314
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-11
- **Primary completion:** 2023-02
- **Final completion:** 2024-02
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02602314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02602314, "Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02602314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*